May 13, 2025

Talk at PEGS Boston 2025: targeting TACAs with high-affinity antibodies

Dr. Peter Sondermann speaks in the oncology stream of the Protein & Antibody Engineering Summit on May 14, 2025.

Announcement of Dr. Peter Sondermann's talk on targeting tumor-associated carbohydrate antigens at PEGS Boston 2025

At PEGS Boston 2025 (May 12–16), Dr. Peter Sondermann presents Novel Targets for Cancer Therapy: Targeting of Tumor-Associated Carbohydrate Antigens with High-Affinity Antibodies in the oncology stream "Emerging Targets for Oncology and Beyond".

Wednesday, May 14, 2025, 3:00 pm EDT, followed by a panel discussion at 3:30 pm.

More news

All news

Apr 29, 2026 Press releases

Tacalyx secures €11 million to advance lead TACA-targeting ADC programme toward the clinic

€11 million from the existing syndicate in a first closing of the seed extension. TCX-201 is selected as first clinical candidate, with a CTA filing planned for 2027.

AACR 2026 poster 5631 on TCX-201, with in vitro, in vivo, pharmacokinetic and toxicology panels

Apr 21, 2026 Scientific presentations

TCX-201 and TCX-101 data presented at AACR 2026

Two posters at the AACR Annual Meeting 2026 in San Diego: the preclinical profile of first clinical candidate TCX-201 (Poster 5631) and TCX-101 as a trispecific T-cell engager (Poster 5584).

Tacalyx April 2026 highlights flyer listing the Scientific Advisory Board meeting in Berlin and the AACR partnering event in San Diego

Apr 9, 2026 Company

April 2026: advisory boards, AACR partnering and two posters

Scientific Advisory Board meeting in Berlin, Clinical Advisory Board meeting and AACR Oncology Industry Partnering Event in San Diego, followed by two posters at AACR 2026.